Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 16,542 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Connective Tissue Disease Clear all

Conditions: Breast Neoplasms
Interventions: Prayer; Behavioral
Lead sponsor: Southwestern Regional Medical Center; Other
Eligibility: 21 Years to 80 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Allergy Skin, Allergy, Dermatitis, Allergic Contact
Interventions: NeoMatriX Wound MatriX Collagen Dressing; Device
Lead sponsor: NeXtGen Biologics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Triple Negative Breast Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small Cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer
Interventions: NKT3964, Paclitaxel, Doxorubicin; Drug
Lead sponsor: NiKang Therapeutics, Inc.; Industry
Eligibility: 19 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 19
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more

Conditions: Systemic Lupus Erythematosus
Interventions: BI 3000202, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 30
States / cities: Beverly Hills, California • La Palma, California • San Diego, California + 27 more

Conditions: Metastatic Breast Cancer
Interventions: Fulvestrant, Tamoxifen, Palbociclib; Drug
Lead sponsor: Shannon Puhalla; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: carboplatin, paclitaxel, cytoreductive surgery; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Basal Cell Carcinoma, Skin Cancer, Cancer of the Skin, Basal Cell, Cancer of the Skin, Carcinoma
Interventions: Part 1: VP-315 3 Day Dosing/Week, Part 2: VP-315 3 Day Dosing/Week - Loading Dose, Part 2: VP-315 3 Day Dosing/Week - No Loading Dose, Part 2: VP-315 2 Day Dosing/Week - Split Dose, Part 2: VP-315 3 Day Dosing/Week - Split Dose; Drug
Lead sponsor: Verrica Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 13
States / cities: San Diego, California • Boca Raton, Florida • Coral Springs, Florida + 9 more

Conditions: Hidradenitis Suppurativa
Interventions: Sonelokimab; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 12 Years and older
Enrollment: 835 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 49
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Breast Cancer, Opioid Use
Interventions: Methadon; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Chronic Spontaneous Urticaria
Interventions: Nucala; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Venous Leg Ulcer
Interventions: Marine polysaccharide dressing, Carboxymethylcellulose dressing; Device
Lead sponsor: Medline Industries; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Fresno, California • Selma, California • Boston, Massachusetts + 2 more

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 9
States / cities: Tucson, Arizona • Los Angeles, California • Santa Rosa, California + 6 more

Conditions: Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions: Exemestane, Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen, Triptorelin; Drug · Other · Procedure + 1 more
Lead sponsor: ETOP IBCSG Partners Foundation; Network
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 3,066 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2024
U.S. locations: 480
States / cities: Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 323 more

Conditions: Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Interventions: Dabrafenib, Spartalizumab, Therapeutic Conventional Surgery, Trametinib; Drug · Biological · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions: Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide, Cyclosporine, Diagnostic Imaging Testing, Echocardiography Test, Fludarabine Phosphate, Multigated Acquisition Scan, Mycophenolate Mofetil, Survey Administration, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation; Procedure · Drug · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 6 Months to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Unresectable Melanoma
Interventions: Ipilimumab, Nivolumab, Lymph Node Assessment, Biospecimen Collection; Biological · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Psoriasis, Plaque Psoriasis
Interventions: Halobetasol Propionate Lotion 0.05%, Placebo; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: San Diego, California • Fridley, Minnesota • Austin, Texas

Conditions: Refractive Errors
Interventions: Acuity 200 (Fluoroxyfocon A) contact lens, Acuity 100 (Hexafocon A) contact lens; Device
Lead sponsor: Acuity Polymers, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Honolulu, Hawaii • Edina, Minnesota • Pittsford, New York

Conditions: Prurigo Nodularis (PN)
Interventions: Lebrikizumab; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Metastatic Breast Cancer, BRCA1 Gene Mutation, brca2 Gene Mutation
Interventions: ABT-888, temozolomide; Drug
Lead sponsor: Steven J Isakoff, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Computed Tomography; Device
Lead sponsor: Koning Corporation; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 401 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Breast Carcinoma
Interventions: Enhanced Consultation, Standard of Care Consultation, Conventional Imaging, Educational Intervention, Questionnaire Administration; Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: exemestane, tamoxifen, triptorelin; Drug
Lead sponsor: ETOP IBCSG Partners Foundation; Network
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 2,672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2024
U.S. locations: 139
States / cities: Burbank, California • La Jolla, California • Mission Hills, California + 106 more

Search by objective public record fields.

Prayer as a Possible Adjuvant Treatment for Breast Cancer

NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

The Impact of Intraoperative Methadone on Postoperative Opioid Use

Mepolizumab for the Treatment of Chronic Spontaneous Urticaria

A Comparative Evaluation of a MPS Dressing and a CMC Dressing on Subjects With Lower Extremity Venous Ulcers

A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995)

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Postoperative Outcomes and Patient Satisfaction With Mayo Clinic Florida Care Hotel After Mastectomy and Tissue Expander Placement

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

Clinical Evaluation of Acuity 200 (Fluoroxyfocon A) RGP Contact Lens

Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients

ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

Cone Beam Computed Tomography for Breast Imaging

Patient-Specific Decision Aid System for Shared Decision Making About Breast Reconstruction

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer